AstraZeneca, Amgen tout Phase 2a Tezspire data in COPD ahead of Dupixent decision

AstraZeneca and Amgen laid out the full Phase 2a dataset for Tezspire in COPD at the American Thoracic Society’s International Conference on Sunday, providing a deeper look at how their immunology drug could potentially compete with Sanofi and Regeneron’s Dupixent.

Although the trial did not achieve statistical significance, as outlined…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks